Canaccord Adams downgrades Idera Pharmaceuticals (Nasdaq: IDRA) from Buy to Hold. The firm maintained its price target of $15.40.

This article: 107 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE